Inter‐individual variability of plasma PAF‐acetylhydrolase activity in ARDS patients and PAFAH genotype

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Clinical Pharmacy and Therapeutics

• Publication date

  2009-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2710.2008.01014.xPMID 19583678
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Platelet-Activating Factor Inactivator (rPAF-AH) Enhances Liver’s Recovery After Paracetamol Intoxication

  2007cited by this paper
• Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial.

  2007influential reference
• EXOGENOUS PLATELET-ACTIVATING FACTOR ACETYLHYDROLASE REDUCES MORTALITY IN MICE WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME AND SEPSIS

  2006cited by this paper
• Recombinant Platelet-Activating Factor–Acetylhydrolase Attenuates Paracetamol-Induced Liver Oxidative Stress, Injury, and Regeneration

  2006cited by this paper
• Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury*

  2005cited by this paper
• Nuclear factor-kappaB- and glucocorticoid receptor alpha- mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids.

  2005cited by this paper
• Plasma platelet-activating factor acetylhydrolase activity in critically ill patients*

  2005cited by this paper
• Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial*

  2004cited by this paper
• Systemic Inflammation‐Associated Glucocorticoid Resistance and Outcome of ARDS

  2004cited by this paper
• Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial.

  2003cited by this paper
• PLATELET‐ACTIVATING FACTOR ACETYLHYDROLASE INHIBITS ALVEOLAR MACROPHAGE ACTIVATION IN VIVO

  2003cited by this paper
• Regulation of Neutrophil Activation in Acute Lung Injury and SIRS

  2002cited by this paper
• The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis

  2002cited by this paper
• Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay

  2002cited by this paper
• PAF acetylhydrolase gene polymorphisms and asthma severity.

  2001cited by this paper
• Neutrophil migration mechanisms, with an emphasis on the pulmonary vasculature.

  2000cited by this paper
• Platelet-activating factor acetylhydrolase and haemophagocytosis in the sepsis syndrome.

  2000cited by this paper
• PAF-induced RANTES production by human airway smooth muscle cells requires both p38 MAP kinase and Erk.

  2000cited by this paper
• Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in japan.

  2000cited by this paper
• The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.

  2000cited by this paper
• Role of P-selectin and ICAM-1 in pancreatitis-induced lung inflammation in rats: significance of oxidative stress.

  1999cited by this paper
• Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice.

  1999cited by this paper
• Molecular Basis of the Interaction between Plasma Platelet-activating Factor Acetylhydrolase and Low Density Lipoprotein*

  1999cited by this paper
• Differential determination of phospholipase A(2) and PAF-acetylhydrolase in biological fluids using fluorescent substrates.

  1999cited by this paper
• Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma.

  1999cited by this paper
• Regulation of neutrophil activation in acute lung injury.

  1999cited by this paper
• Reduced PAF-acetylhydrolase activity is associated with postinjury multiple organ failure. David A. Partrick, Ernest E. Moore, Frederick A. Moore, Walter L. Biffl, and Carlton C. Barnett. Shock 7:170-174, 1997.

  1998cited by this paper
• Platelet-activating factor plays a pivotal role in the induction of experimental lung injury.

  1998cited by this paper
• Depressed Plasma Platelet- Activating Factor Acetylhydrolasein Pat ients Presenting with Acute Myocardial Infarction

  1998cited by this paper
• Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.

  1998cited by this paper
• Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS

  1998cited by this paper
• Host defense response and outcome in ARDS.

  1997cited by this paper
• A mutation in plasma platelet-activating factor acetylhydrolase (Val279-->Phe) is a genetic risk factor for stroke.

  1997cited by this paper
• Platelet-activating Factor Acetylhydrolases*

  1997cited by this paper
• Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281-->Arg mutation.

  1997cited by this paper
• REDUCED PAF‐ACETYLHYDROLASE ACTIVITY IS ASSOCIATED WITH POSTINJURY MULTIPLE ORGAN FAILURE

  1997cited by this paper
• Acute respiratory distress syndrome: consensus, definitions, and future directions.

  1996cited by this paper
• Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.

  1996cited by this paper
• Interactions between neutrophils and cytokines in blood and alveolar spaces during ARDS.

  1996cited by this paper
• Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

  1995cited by this paper
• Plasma degradation of platelet‐activating factor in severely ill patients with clinical sepsis

  1994cited by this paper
• Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Consensus Committee.

  1994cited by this paper
• Platelet-activating factor receptor and signal transduction.

  1992influential reference
• Performing the exact test of Hardy-Weinberg proportion for multiple alleles.

  1992cited by this paper
• High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis.

  1992cited by this paper
• The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults.

  1991cited by this paper
• Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates.

  1991cited by this paper
• An early test of survival in patients with the adult respiratory distress syndrome. The PaO2/FIo2 ratio and its differential response to conventional therapy. Prostaglandin E1 Study Group.

  1989cited by this paper
• Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.

  1989influential reference
• An expanded definition of the adult respiratory distress syndrome.

  1988cited by this paper
• Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children.

  1988cited by this paper
• High-dose corticosteroids in patients with the adult respiratory distress syndrome.

  1987cited by this paper

• Mannose-6-phosphate attenuates acute lung injury by competitive release of acid sphingomyelinase from the mannose-6-phosphate receptor in endothelial caveolae

  2025cites this paper
• Animal models of infection-induced acute lung injury

  2024cites this paper
• Liang-Ge Decoction Ameliorates Coagulation Dysfunction in Cecal Ligation and Puncture-Induced Sepsis Model Rats through Inhibiting PAD4-Dependent Neutrophil Extracellular Trap Formation

  2023cites this paper
• Platelet Activating Factor Activity Modulates Hyperoxic Neonatal Lung Injury Severity

  2023cites this paper
• The lipid biology of sepsis

  2021cites this paper
• G994T polymorphism in exon 9 of plasma platelet-activating factor acetylhydrolase gene and lung ultrasound score as prognostic markers in evaluating the outcome of acute respiratory distress syndrome.

  2019cites this paper
• Acute Respiratory Distress Syndrome: Biomarkers, Mechanisms, and Water Channels.

  2019cites this paper
• G 994 T polymorphism in exon 9 of plasma platelet ‐ activating factor acetylhydrolase gene and lung ultrasound score as prognostic markers in evaluating the outcome of acute respiratory distress syndrome

  2019cites this paper
• Impact of a non‐synonymous Q281R polymorphism on structure of human Lipoprotein‐Associated Phospholipase A2 (Lp‐PLA2)

  2018cites this paper
• Markers of anaphylaxis - a systematic review.

  2018cites this paper
• Znaczenie osoczowej acetylohydrolazy PAF w chorobach alergicznych – aktualny stan wiedzy

  2016cites this paper
• Platelets in the immune response: Revisiting platelet-activating factor in anaphylaxis.

  2015cites this paper
• Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population

  2014cites this paper
• The prevalence of platelet activating factor acetylhydrolase single nucleotide polymorphisms in relationship to necrotizing enterocolitis in Northwest Louisiana infants

  2013cites this paper
• Lung endothelial Ca2+ and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6.

  2012cites this paper
• Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: a systematic review of the literature.

  2012cites this paper
• Vascular Barrier Regulation by PAF, Ceramide, Caveolae, and NO - an Intricate Signaling Network with Discrepant Effects in the Pulmonary and Systemic Vasculature

  2010cites this paper
• The Scope of Pharmacological and Clinical Effects of Modern Antihistamines, With a Special Focus on Rupatadine: Proceedings from a Satellite Symposium held at the 21st World Allergy Congress, Buenos Aires, December 8, 2009

  2010cites this paper
• The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses.

  2010cites this paper
• Functional Consequences of Mutations and Polymorphisms in the Coding Region of the PAF Acetylhydrolase (PAF-AH) Gene

  2009cites this paper